alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Michigan Supreme Court

Lansing, Michigan

Marilyn Kelly,

 Chief Justice

Michael F. Cavanagh

Elizabeth A. Weaver

Maura D. Corrigan

Robert P. Young, Jr.

Stephen J. Markman

Diane M. Hathaway, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

 _________________________________________ 

 Clerk

April 27, 2010 

s0419 

Order 

 

April 27, 2010 

140417 

PEOPLE OF THE STATE OF MICHIGAN, 

Plaintiff-Appellee, 

v SC: 140417 

 COA: 286959 

Wayne CC: 08-002798-FC 

BRIAN DANGELO BROOKS, 

Defendant-Appellant. 

_________________________________________/ 

 On order of the Court, the application for leave to appeal the December 3, 2009 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the question presented should be reviewed by this Court.
CS 315822-A 03/12/2020

상세 정보: www.cdc.gov/COVID19

집에서 호흡계 관련 증상을 관리하는 10가지 방법

발열, 기침, 숨가쁨 증상이 있으면 의료기관에 전화하세요. 집에서 증상을 관리하라는 지시를 

받을 수도 있습니다. 다음의 안내를 따르십시오.

6. 기침과 재채기를 할 때에는 

가리세요.

2. 자신의 증상을 주의깊게 

관찰하세요 만약 증상이 

악화되는 경우, 즉시 

의료기관에 전화하세요

4. 진료 약속이 있는 경우, 

미리 의료기관에 

전화하여 COVID-19에 

걸렸거나 감염 가능성이 

있다고 알리십시오.

7. 손을 자주 씻으세요. 비누와 

물로 손을 최소 20초 동안 

씻거나, 알코올 성분이 60% 이상 

함유된 위생 소독제를 사용하여 

손을 청결히 하세요. 

8. 가능하면 정해진 방에 머무르고

집안의 다른 사람들로부터 

떨어져 있어야 합니다. 또한 

가능하면 별도의 화장실을 

사용해야 합니다. 집 안이나 밖에서 

다른 사람 근처에 가게되는 경우 

마스크를 착용하세요.

1. 집에 머무르세요. 출근 또는 

등교를 하지 마시고 공공 장소

에 가지 마십시오. 외출해

야 할 경우 대중교통, 공유 차량, 

택시를 이용하지 마십시오.

9. 집에서 식기, 수건, 침구 등 

개인 용품을 다른 사람과 

함께 사용하지 마세요.

3. 휴식을 취하고 수분을 

잘 섭취하세요. 

10. 카운터, 탁자 위, 문고리 등 

자주 만지는 표면을 모두 

청소하세요. 라벨에 표시된 

지침에 따라 청소용 스프레이나 

청소포를 사용하세요.

5. 의학적 응급 상황이 발생한 

경우 911로 전화하여 

COVID-19에 걸렸거나 그럴 

가능성이 있다고 파견 

담당자에게 알려주십시오.
Exhibit 10.2

                            BARRY L . FRIEDMAN, P.C.
                           Certified Public Accountant


1582 TULITA DRIVE                                        OFFICE (702) 361-8414
LAS VEGAS, NEVADA  89123                                 FAX NO (702) 896-0278


January 4, 2000


Securities Exchange Commission
450 Fifth Street
Washington, DC  20549

Ladies and Gentlemen:

We have read the statements made by BrowseSafe.com, Inc., in its Amendment No. 1
to Form 10SB, Part II, Item 3, which we understand will be filed with the
Commission pursuant to Regulation SB. We agree with the statements in these
paragraphs concerning our firm.

Very truly yours,


/s/ BARRY L. FRIEDMAN

BARRY L. FRIEDMAN, P.C.
K315822- CS 05/01/2020

coronavirus/gov.cdc

که تاسې ممکن یا تایید شوی کویډ – 19 لرئ:

خولهپټهکړئ. .6 دټوخی اوپرنجی پرمهال مو

.2 خپل عالیم

په دقت رسه نظارت کړئ. که ستاسې

عالیم وخیم کیږي یا سختیږي نو

سمدالسه خپل د روغتیا پاملرنې وړاندې

کونکي ته تلیفون وکړئ. 

.4 که طبي مالقات یا د ډاکټر رسه

مالقات لرې، نودوختنهمخکې

روغتیاپال یاډاکټر ته تلیفون وکړه

او ورته ووایه چې کويډ – 19 باندې

اخته یې یا شاید اخته اوسې.

20 ثانیی په صابون او اوبو ومینځئ یا د .7 خپل السونهډیر ځلهلږترلږه

الکولوالس پاکونکي داسې موادو )سنیټایزر( 

رسه خپل السونه پاک کړئ چې لږترلږه %60

الکول ولري. 

.8 په خپل کور کې د امکان تر حد پورې په یوه

ځانګړې خونه کې او دنورو خلکونهلیرې

و اوسیږې. همدارنګه، که موجود وي نو باید

جال حامم وکاروې. که تاسې اړ یې چې په کور

کې دننه یا بهر د نورو خلکو شاوخوا اوسئ، نو

ماسک واغوندئ.

ځئ. او د نورو عامه ځایونو نه لیرې اوسیږئ. .1 پهکور کې پاتې شئ کار یا ښوونځي ته مه

که تاسې اړ یې چې بهر تهالړشئ، هیڅ

ډول عامه ټرانسپورټیشن، ګډه سپريل یا ګډ

ټرانسپورټ، یا ټیکيس مه کاروئ.

.9 پهکورنۍ کې د نورو خلکو رسه خپل

شخيص شیان مه رشیکوئ، لکه لوخي یا

قابونه، جان پاکونه، او د ویده کیدو

تخت لوازم.

.3 اراموکړئ اومایعات وڅښئ. 

1010ټولې هغه سطحې چې ډیرې ملس کیږي

پاکوئ لکه کاونټرونه، میزونه، او د دروازو

الستي. د کور پاکولو سپری ګانې یا جارو د

لیبل الرښوونو مطابق وکاروئ.

.5 د عاجل طبي حاالتو لپاره، 911

شمیرې ته تلیفون وکړئ او دپیغام

ترالسهکونکي پرسونل ته خرب

ورکړئ چې ته کويډ – 19 باندې

اخته یې یا شاید اخته اوسې.

10 هغه شیان چې تاسې یې پهکور کې د خپلوکویډ– 19

عالیمومدیریت کولولپارهکولی شئ
### §408d. Addition of lands purchased within boundaries for conservation or forestation purposes

All lands purchased from funds heretofore allocated and made available by Executive order, or otherwise, for the acquisition of lands for conservation or forestation purposes within the maximum boundaries of the Isle Royale National Park, as authorized by sections 408 to 408b of this title, are made a part of the said park as fully as if originally acquired for that purpose and the proviso at the end of section 408 of this title shall not be construed so as to prohibit the acquisition of lands in the park area with the aforesaid funds.

(June 20, 1938, ch. 531, 52 Stat. 785.)
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

KY/Research

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

ANGELITA DAGSIL AGRIPA,

 Petitioner,

 v.

ERIC H. HOLDER Jr., Attorney General,

 Respondent.

No. 06-70141

Agency No. A029-418-871

MEMORANDUM *

On Petition for Review of an Order of the

Board of Immigration Appeals

Submitted December 15, 2009** 

Before: GOODWIN, WALLACE, and FISHER, Circuit Judges. 

Angelita Dagsil Agripa, a native and citizen of the Philippines, petitions for

review of the Board of Immigration Appeals’ (“BIA”) order denying her motion to

reconsider and reopen. We have jurisdiction under 8 U.S.C. § 1252. We review

FILED

DEC 23 2009

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
KY/Research 2 06-70141

for abuse of discretion the denial of a motion to reopen or reconsider, and review

de novo claims of due process violations. Cano-Merida v. INS, 311 F.3d 960, 964

(9th Cir. 2002). We deny the petition for review.

The BIA did not abuse its discretion in denying Agripa’s motion as untimely

because the motion was filed almost 10 months after the BIA’s December 21,

2004, order dismissing the underlying appeal, see 8 C.F.R. § 1003.2(b)(2), (c)(2),

and Agripa failed to establish grounds for equitable tolling, see Iturribarria v. INS,

321 F.3d 889, 897 (9th Cir. 2003) (equitable tolling available where “petitioner is

prevented from filing because of deception, fraud, or error, as long as the petitioner

acts with due diligence”). It follows that Agripa has not established a due process

violation. See Lata v. INS, 204 F.3d 1241, 1246 (9th Cir. 2000) (requiring error to

succeed on a due process claim).

PETITION FOR REVIEW DENIED.
UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 
 FORM 8-K
 
 CURRENT REPORT
 Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
 Date of Report (Date of earliest event reported) May 10, 2010
 
 Progenics Pharmaceuticals, Inc.
 (Exact name of registrant as specified in its charter)
 
 Delaware

000-23143

13-3379479(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)777 Old Saw Mill River Road, Tarrytown, New York

10591(Address of principal executive offices)

(Zip Code)Registrant's telephone number, including area code (914) 789-2800
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
 
 
 oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
  
  Item 2.02.                      Results of Operations and Financial Condition.
  Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its operational results for the quarter ended March 31, 2010.  A copy of its press release is attached hereto as Exhibit 99.1.
   The information furnished pursuant to Item 2.02 in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Exchange Act or the Securities Act of 1933. We undertake no duty or obligation to publicly update or revise the information so furnished.
  Item 9.01.                      Financial Statements and Exhibits.
 
 (d) Exhibits
 
 Exhibit No.                      Description
 
 99.1                      Press Release dated May 10, 2010.
 
  
  SIGNATURES
 
 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 PROGENICS PHARMACEUTICALS, INC.
 By:/s/ ROBERT A. MCKINNEY
 Robert A. McKinney
 Chief Financial Officer, Senior Vice President,
 Finance & Operations and Treasurer
 
 
 
 Date: May 10, 2010
Lo que significan los resultados de su prueba

Si la prueba del COVID-19 le da positivo

TOME MEDIDAS PARA AYUDAR A PREVENIR LA PROPAGACIÓN DEL COVID-19

QUÉDESE EN CASA. 

No salga de casa, excepto 

para buscar atención médica. 

No visite áreas públicas.

DESCANSE Y MANTÉNGASE 

HIDRATADO. 

Tome medicamentos de venta 

libre, como acetaminofeno, para 

que lo ayuden a sentirse mejor.

Si la prueba del COVID-19 le da negativo

• Probablemente no estaba infectado en el momento en que le tomaron 

la muestra. 

• Sin embargo, eso no significa que no se enfermará. 

• Es posible que apenas estuviera comenzando la infección cuando le tomaron 

la muestra y que pudiera dar positivo más adelante. 

Versión accesible en https://espanol.cdc.gov/coronavirus/2019-ncov/testing/diagnostic-testing.html

MANTÉNGASE EN CONTACTO 

CON SU MÉDICO.

SEPÁRESE DE LAS 

DEMÁS PERSONAS.

En la medida de lo posible, 

permanezca en una habitación 

específica y lejos de las otras 

personas y mascotas en su casa.

Un resultado 

negativo en 

la prueba no

significa que no 

se enfermará 

más adelante.

CDC.GOV/CORONAVIRUS-ES

317369-B June 3, 2020 11:47 AM
§ 5.206 Language and wording of registration statement. ( a ) Except as provided in the next sentence, each statement, amendment, exhibit, or notice required to be filed under the Act shall be submitted in the English language. An exhibit may be filed even though it is in a foreign language if it is accompanied by an English translation certified under oath by the translator before a notary public, or other person authorized by law to administer oaths for general purposes, as a true and accurate translation.
( b ) A statement, amendment, exhibit, or notice required to be filed under the Act should be typewritten, but will be accepted for filing if it is written legibly in ink, or if it is filed in an electronic format acceptable to the Registration Unit.
( c ) Copies of any document made by any of the duplicating processes may be filed pursuant to the Act if they are clear and legible.
( d ) A response shall be made to every item on each pertinent form, unless a registrant is specifically instructed otherwise in the form. Whenever the item is inapplicable or the appropriate response to an item is “none,” an express statement to that effect shall be made.
[Order No. 376-67, 32 FR 6362, Apr. 22, 1967, as amended by Order No. 2674-2003, 68 FR 33630, June 5, 2003]
#### § 5.303 Exemption available to persons accredited to international organizations.

Persons designated by foreign governments as their representatives in or to an international organization, other than nationals of the United States, are exempt from registration under the Act in accordance with the provisions of the International Organizations Immunities Act, if they have been duly notified to and accepted by the Secretary of State as such representatives, officers, or employees, and if they engage exclusively in activities which are recognized as being within the scope of their official functions.
#### The People of the State of New York, Respondent, v Ian Harewood, Appellant.

[824 NYS2d 527]

Appeal from a judgment of the Monroe County Court (John J. Connell, J.), rendered January 30, 2002. The judgment convicted defendant, upon a jury verdict, of murder in the second degree and attempted robbery in the first degree (two counts).

It is hereby ordered that the judgment so appealed from be and the same hereby is unanimously affirmed.

Memorandum: Defendant appeals from a judgment convicting him following a jury trial of murder in the second degree (Penal Law § 125.25 [3] [felony murder]) and two counts of attempted robbery in the first degree (§§ 110.00, 160.15 [2], [4]). Contrary to defendant’s contention, the rulings by County Court on vari*1255ous issues did not in effect allow the People to change their theory of the case during trial *(cf. People v Roberts,*72 NY2d 489, 497 [1988]; *People v Orso,*270 AD2d 947, 948 [2000], *lv denied*95 NY2d 856 [2000]; *People v Fata,*184 AD2d 206 [1992], *lv denied*80 NY2d 974 [1992]; *People v Powell,*153 AD2d 54 [1989], *lv denied*75 NY2d 969 [1990]). Also contrary to defendant’s contentions, the evidence is legally sufficient to support the conviction, and the verdict is not against the weight of the evidence *(see generally People v Bleakley,*69 NY2d 490, 495 [1987]).

We reject the further contention of defendant that the statements of an accomplice were not declarations against penal interest and thus were improperly admitted at trial *(see generally People v Brensic,*70 NY2d 9, 15-16 [1987], *mot to amend remittitur granted*70 NY2d 722 [1987]; *People v Settles,*46 NY2d 154, 167 [1978]). We also reject his contention that his statements to the police were not sufficiently corroborated *(see generally*CPL 60.50; *People v*Chico, 90 NY2d 585, 589-590 [1997]; *People v Daniels, 37*NY2d 624, 629 [1975]).

Defendant failed to preserve for our review his challenge to the court’s jury instructions *(see People v Ponder,*19 AD3d 1041, 1042-1043 [2005], *lv denied*5 NY3d 809 [2005]; *People v Halberg,*254 AD2d 808 [1998]; *see also People v Swail,*19 AD3d 1013 [2005], *lv denied*6 NY3d 759, 853 [2005]), nor did he preserve for our review his challenge to the court’s failure to grant a mistrial after striking the testimony of two witnesses *(see People v Pross,*302 AD2d 895, 897 [2003], *lv denied*99 NY2d 657 [2003]). We decline to exercise our power to review those challenges as a matter of discretion in the interest of justice *(see*CPL 470.15 [6] [a]). Finally, we conclude that the evidence, the law, and the circumstances of this case, viewed in totality and as of the time of the representation, establish that defendant received meaningful representation *(see generally People v Baldi,*54 NY2d 137, 147 [1981]). Present—Kehoe, J.P., Martoche, Centra, Green and Pine, JJ.
CERTIFICATIONS REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a)

I, David P. Hall, Chairman, President and Chief Executive Officer of Aurizon Mines Ltd., certify that:

1.

I have reviewed this annual report on Form 40-F of Aurizon Mines Ltd. (the Issuer);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Issuer as of, and for, the periods presented in this report;

4.

The Issuers other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Issuer and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Evaluated the effectiveness of the Issuers disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c)

Disclosed in this report any change in the Issuers internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Issuers internal control over financial reporting; and

5.

The Issuers other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Issuers auditors and the audit committee of Issuers board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Issuers ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Issuers internal control over financial reporting.



/s/ David P. Hall________________________________________
David P. Hall
Chairman, President and Chief Executive Officer

March 31, 2006
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

TENET HOSPITALS LIMITED d/b/a 

SIERRA MEDICAL CENTER,

 Appellant,

v.

SANDRA BERNAL, Individually and as 

Independent Administrator of the Estate of 

Margarita G. Medrano, Deceased, 

CAROLINA HERNANDEZ, CARLOS M. 

MEDRANO, MARIA MAGDALENA 

ALEXUS, RAUL MEDRANO AND 

MARIA V. TELLEZ,

 Appellees.

§

§

§

§

§

§ 

§

§ 

No. 08-14-00181-CV

Appeal from the

120th Judicial District Court 

of El Paso County, Texas 

(TC#2013DCV3968) 

J U D G M E N T

The Court has considered this cause on the record and concludes there was error in the 

trial court’s order denying Appellant’s motion to dismiss. We therefore reverse the trial court’s 

order denying Appellant’s motion to dismiss and remand for the trial court to consider granting 

Appellees a thirty-day extension to cure their expert reports, in accordance with our opinion.

We further order that each party bear their own appellate costs, for which let execution 

issue. This decision shall be certified below for observance.

IT IS SO ORDERED THIS 18TH DAY OF NOVEMBER, 2015.

STEVEN L. HUGHES, Justice

Before Rodriguez, J., Hughes, J., and Larsen, J. (Senior Judge)

Larsen, J. (Senior Judge), sitting by assignment
## Breadcrumb

-  Home 
-  SBA Leadership 
-  Diedra Henry-Spires 

#   Diedra Henry-Spires 

Senior Advisor for COVID Programs

            Download high-resolution image          

Ms. Henry-Spires has been selected to serve as the Senior Advisor for COVID Programs to the Administrator at the U.S. Small Business Administration. In this role, Ms. Spires has been tasked with improving and enhancing the efficiency of COVID programs from application to award.  As such, she works closely with the Administrator, The White House, Capitol Hill, and Stakeholders to ensure that the relief needed by small businesses across the country is made available and accessible. 

Ms. Henry-Spires is a top advocacy and policy strategist and a former Professional Staff Member, for Human Services and Income Security, for the Senate Committee on Finance. As a former member of the Committee’s Health Team, she is credited as one of the architects of the Affordable Care Act.  As well, Ms. Henry-Spires is credited with shepherding the expansion of unemployment benefits and work supports during the great recession of 2008 and providing job creation policy and income security guidance and expertise for the American Recovery and Reinvestment Act of 2009 (ARRA), Jobs Creation Act of 2010, The American Taxpayer Relief Act of 2012, and The Middle-Class Tax Relief and Job Creation Act of 2012. Since leaving the Hill in 2014, Ms. Henry-Spires has served as the CEO of The Dalton Daley Group for Children and Families, a Maryland based nonprofit. 

Ms. Henry-Spires holds a B.S. in Health Policy and Administration from the Pennsylvania State University, a Certificate in Delivery System Reform from the Harvard John F. Kennedy School of Government and was a Brookings Institute LEGIS Fellow.  She is currently a lecturer in Public Policy and Health Policy for the University of Texas, Archer Center in Washington D.C.
UNITED STATES OF AMERICA

Before the

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Administrative Proceedings Rulings

Release No. 6838 / March 24, 2022

Administrative Proceeding

File No. 3-17228

In the Matter of

David S. Hall, P.C. d/b/a The Hall 

Group CPAs,

David S. Hall, CPA,

Michelle L. Helterbran Cochran, 

CPA, and

Susan A. Cisneros

Order Granting Joint Motion

Today, the parties jointly moved to stay this proceeding pending the 

Supreme Court’s ruling on a petition for a writ of certiorari from Cochran v. 

SEC, 20 F.4th 194 (5th Cir. 2021) (en banc). The Department of Justice 

recently filed the petition on behalf of the Securities and Exchange 

Commission.

I construe the motion as a request to postpone the hearing and other 

deadlines. See 17 C.F.R. § 201.161; Paul Free, CPA, Securities Exchange Act of 

1934 Release No. 66260, 2012 WL 266986, at *2 (Jan. 26, 2012); see also 

Pending Admin. Proc., Securities Act of 1933 Release No. 10536, 2018 WL 

4003609, at *2 n.7, *6 (Aug. 22, 2018). For good cause shown, I GRANT the 

motion. Deadlines are postponed until the Supreme Court issues a decision on 

whether to grant the petition. Within two weeks of that decision, the parties 

shall file a motion or status update about whether further postponement will 

be necessary.

/s/ Jason S. Patil

Administrative Law Judge
### §1203. Authorization of appropriations

There is authorized to be appropriated not to exceed $500,000 for the fiscal year ending June 30, 1968, $750,000 for the fiscal year ending June 30, 1969, $1,000,000 for the period beginning July 1, 1969, and ending June 30, 1973, and $400,000 for each of the fiscal years ending June 30, 1974, June 30, 1975, June 30, 1976, and June 30, 1977.

(Pub. L. 89–720, §3, Nov. 2, 1966, 80 Stat. 1149; Pub. L. 91–451, Oct. 14, 1970, 84 Stat. 922; Pub. L. 92–604, Oct. 31, 1972, 86 Stat. 1493.)

#### **Editorial Notes**

#### Amendments

1972—Pub. L. 92–604 authorized appropriations of $400,000 for fiscal years ending June 30, 1974, 1975, 1976, and 1977.

1970—Pub. L. 91–451 substituted "for the period beginning July 1, 1969, and ending June 30, 1973" for "for the fiscal year ending June 30, 1970".